[Federal Register: June 19, 2003 (Volume 68, Number 118)]
[Notices]
[Page 36844]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr19jn03-86]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of title 21 of the Code of Federal
Regulations (CFR), this is notice that on July 23, 2001, and April 21,
2003, Eli-Elsohly Laboratories, Inc., Mahmoud A. Elsohly Ph.D., 5
Industrial Park Drive, Oxford, Mississippi 38655, made application by
renewal to the Drug Enforcement Administration (DEA) for registration
as a bulk manufacturer of the basic classes of Schedule I and II
controlled substances listed below:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)............................... I
Dihydromorphine (9145)..................................... I
Amphetamine (1100)......................................... II
Methamphetamine (1105)..................................... II
Cocaine (9041)............................................. II
Codeine (9050)............................................. II
Dihydrocodeine (9120)...................................... II
Oxycodone (9143)........................................... II
Hydromorphone (9150)....................................... II
Benzoylecognine (9180)..................................... II
Hydrocodone (9193)......................................... II
Morphine (9300)............................................ II
------------------------------------------------------------------------
The firm plans to manufacture non-deuterated controlled substances
for use as analytical standards and deuterated controlled substances
for use as internal standards.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances may file comments or objections
to the issuance of the proposed registration.
Any such comments or objections may be addressed, in quintuplicate,
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, United States Department of Justice,
Washington, DC 20537, Attention: DEA Federal Register Representative
(CCD) and must be filed no later than August 18, 2003.
Dated: June 6, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 03-15536 Filed 6-18-03; 8:45 am]
BILLING CODE 4410-09-M